Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2014 Oct 19;41(6):675–691. doi: 10.1007/s10928-014-9393-x

Table 3.

Parameter estimates, inter-animal variability (IIV as CV%) and corresponding relative standard errors (%RSE) for the plasma PK-cellular signaling-tumor burden model with pooled data from AMG925 and sorafenib studies

Parameter (units) Description Mean (%RSE) IIV CV% (%RSE)
λ0 (h−1) Exponential tumor growth rate 0.0104 (5.9) 25.2 (17)
λ1 (mm3*h−1) Linear tumor growth rate 11.2 (23) 43.5 (36)
kpSTAT5 Rate of net tumor growth suppression due to the inhibition of STAT5 phosphorylation 0.854 (24) 26.7 (71)
kpRb Rate of net tumor growth suppression due to the inhibition of Rb phosphorylation 0.554 (28) 37.6 (52)
TV(0) (mm3) Initial tumor burden 211 (3.2) 15.3 (22)